Technical Analysis for RDY - Dr. Reddy's Laboratories Ltd

Grade Last Price % Change Price Change
B 75.41 -1.02% -0.78
RDY closed down 1.02 percent on Monday, July 1, 2024, on 1.17 times normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up

Date Alert Name Type % Chg
Slingshot Bullish Bullish Swing Setup 0.00%
Upper Bollinger Band Walk Strength 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Stochastic Reached Overbought Strength -1.02%
Upper Bollinger Band Walk Strength -1.02%
Above Upper BB Strength -1.02%
Gapped Up Strength -1.02%
Overbought Stochastic Strength -1.02%
Up 3 Days in a Row Strength -1.02%

   Recent Intraday Alerts

Alert Time
Down 1% about 10 hours ago
60 Minute Opening Range Breakdown about 10 hours ago
Fell Below Previous Day's Low about 11 hours ago
Fell Below Upper Bollinger Band about 11 hours ago
Up 1 ATR 3 days ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Dr. Reddy's Laboratories Ltd Description

Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company. It operates in three segments: Pharmaceutical services and Active Ingredients (PSAI), Global Generics, and Proprietary Products. The PSAI segment develops active pharmaceutical ingredients (APIs) and intermediaries, which are used as principal ingredients for finished pharmaceutical products. This segment also offers contract research services to biotech and pharmaceutical companies; and manufactures and sells APIs and steroids in accordance with the specific customer requirements. The Global Generics segment produces and markets finished pharmaceutical products as branded formulations or generic finished dosages. This segment also engages in the operation of biologics business. The Proprietary Products segment engages in the discovery and development of new chemical entities for subsequent commercialization and out-licensing. It offers new, synergistic combination, and technology formulations that modifies pharmacokinetics of existing medicines. This segment is also involved in the Company's specialty pharmaceuticals business that includes sales and marketing operations for in-licensed and co-developed dermatology. The company offers its products and services primarily in the areas of gastrointestinal, cardiovascular, pain management, and oncology therapies. It primarily operates in India, the United States, Russia and other countries of the former Soviet Union, Europe, and others. Dr. Reddy's Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Pharmaceutical Products Gastrointestinal Dermatology Pain Management Active Pharmaceutical Ingredients Pharmacokinetics Chemical Entities Oncology Therapies Contract Research Services Pharmaceutical Industry In India Pharmaceutical Services Biotech And Pharmaceutical

Is RDY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 77.72
52 Week Low 61.1579
Average Volume 267,061
200-Day Moving Average 70.33
50-Day Moving Average 71.48
20-Day Moving Average 71.90
10-Day Moving Average 72.78
Average True Range 1.18
RSI (14) 65.87
ADX 18.88
+DI 43.16
-DI 20.36
Chandelier Exit (Long, 3 ATRs) 73.30
Chandelier Exit (Short, 3 ATRs) 71.60
Upper Bollinger Bands 75.67
Lower Bollinger Band 68.13
Percent B (%b) 0.97
BandWidth 10.48
MACD Line 1.01
MACD Signal Line 0.49
MACD Histogram 0.5167
Fundamentals Value
Market Cap 12.56 Billion
Num Shares 167 Million
EPS 3.77
Price-to-Earnings (P/E) Ratio 20.00
Price-to-Sales 0.05
Price-to-Book 3.82
PEG Ratio 4.87
Dividend 40.00
Dividend Yield 53.04%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 77.00
Resistance 3 (R3) 77.08 76.64 76.74
Resistance 2 (R2) 76.64 76.23 76.60 76.65
Resistance 1 (R1) 76.02 75.98 75.80 75.94 76.56
Pivot Point 75.58 75.58 75.47 75.54 75.58
Support 1 (S1) 74.96 75.17 74.74 74.88 74.26
Support 2 (S2) 74.52 74.92 74.48 74.17
Support 3 (S3) 73.90 74.52 74.09
Support 4 (S4) 73.82